Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

PURPOSE: Lorlatinib is a third-generation tyrosine kinase inhibitor currently approved for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. This open-label, phase 1, randomized two-sequence, two-treatment, two-period, crossover study investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibma, Jennifer E., O’Gorman, Melissa, Nepal, Sunil, Pawlak, Sylvester, Ginman, Katherine, Pithavala, Yazdi K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933379/
https://www.ncbi.nlm.nih.gov/pubmed/34698901
http://dx.doi.org/10.1007/s00280-021-04368-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933379/
https://www.ncbi.nlm.nih.gov/pubmed/34698901
http://dx.doi.org/10.1007/s00280-021-04368-1

Ejemplares similares